Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Liabilities and Shareholders Equity (2016 - 2025)

Neuroone Medical Technologies' Liabilities and Shareholders Equity history spans 14 years, with the latest figure at $8.6 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 32.08% year-over-year to $8.6 million; the TTM value through Dec 2025 reached $34.6 million, up 56.23%, while the annual FY2025 figure was $10.8 million, 100.85% up from the prior year.
  • Liabilities and Shareholders Equity reached $8.6 million in Q4 2025 per NMTC's latest filing, down from $10.8 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $17.2 million in Q4 2021 to a low of $4.5 million in Q1 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $8.9 million, with a median of $8.3 million recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: tumbled 50.24% in 2023, then skyrocketed 120.24% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $17.2 million in 2021, then crashed by 43.78% to $9.7 million in 2022, then crashed by 39.73% to $5.8 million in 2023, then increased by 11.54% to $6.5 million in 2024, then skyrocketed by 32.08% to $8.6 million in 2025.
  • Per Business Quant, the three most recent readings for NMTC's Liabilities and Shareholders Equity are $8.6 million (Q4 2025), $10.8 million (Q3 2025), and $10.8 million (Q2 2025).